Cure8 research brief
SpA is a frequent but underrecognized extraintestinal manifestation in people with IBD; validated screening tools can help identify patients who need rheumatology evaluation. Earlier detection may address joint symptoms that otherwise go unrecognized in routine GI care.
Gastroenterologists, rheumatologists, clinicians involved in IBD care, researchers developing screening tools, and adult patients with IBD (and caregivers/clinicians for pediatric IBD due to the current absence of validated pediatric tools).
This article reviewed studies up to August 2025 and included 14 studies (all in adults) from academic/tertiary centers. Six studies evaluated validation performance of screening tools: DETAIL and IBIS-Q (and study-specific structured screens).
Reported sensitivity ranged broadly (about 43–93%) and specificity about 62–90%; having ≥3 positive items on these tools was repeatedly associated with a substantially higher post-test probability of SpA. Imaging (including sacroiliitis assessment) was often used alongside the questionnaires to establish prevalence.
Because all studies were from referral centers, prevalence estimates (reported ≈5–30%) may be higher than in general community practice. Additional practical points: The review found no validated screening tools studied in pediatric IBD populations, highlighting a gap.
The authors emphasize coordinated gastroenterology–rheumatology pathways to refine and implement screening for earlier detection and care.
The included studies were all performed in academic or tertiary referral centers, which may overrepresent more complex IBD cases and increase estimated SpA prevalence. The article is a scoping review based on studies up to August 15, 2025 and the structured content provided is the article abstract.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Detecting neoplasia early is a central goal of IBD surveillance; this study suggests virtual chromoendoscopy may find more lesions than dye or white light in real-world practice, which could influence how surveillance is...
IBD may involve small-vessel changes beyond the gut. If reproducible, retinal microvascular alterations detectable by OCTA could offer a non-invasive window into systemic microvascular involvement in IBD.
New PET tracers like FAPI could better detect fibrosis and stromal activity than standard FDG-PET, which may improve imaging of fibrostenotic Crohn's disease. For people with IBD, improved imaging might eventually help...
